Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2009
06/17/2009EP2069374A1 Crystalline solvates and complexes of (is) -1, 5-anhydro-l-c- (3- ( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
06/17/2009EP2069371A1 Organo-arsenoxide compounds and use thereof
06/17/2009EP2069365A1 Novel 5,7-disubstituted [1, 3]thiazolo [4, 5d]pyrimidin-2 (3h)-amine derivatives and their use in therapy
06/17/2009EP2069364A1 Novel 5, 7-disubstituted [1, 3]thiazolo [4, 5-d]pyrimidin-2 (3h)-one derivatives and their use in therapy
06/17/2009EP2069363A1 Rifaximin
06/17/2009EP2069360A2 Polymorphic forms of spirapril hydrochloride
06/17/2009EP2069359A1 Aza-benzothiophenyl compounds and methods of use
06/17/2009EP2069355A1 Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
06/17/2009EP2069354A1 Aza-benzofuranyl compounds and methods of use
06/17/2009EP2069353A1 Polycyclic agents for the treatment of respiratory syncytial virus infections
06/17/2009EP2069352A2 Certain chemical entities, compositions and methods
06/17/2009EP2069351A2 Pyrazoloquinazolinones as parp inhibitors
06/17/2009EP2069350A2 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
06/17/2009EP2069349A2 Pyrazolopyrimidines as cyclin dependent kinase inhibitors
06/17/2009EP2069348A2 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
06/17/2009EP2069347A2 Novel inhibitors of beta-lactamase
06/17/2009EP2069346A1 Acetamide and carboxamide derivatives of azaadamantane and methods of use thereof
06/17/2009EP2069345A2 Pyridazine and pyrrole compounds, processes for obtaining them and uses
06/17/2009EP2069342A1 2-aryl-6-phenylimidazo[1,2-alpha]pyridine derivatives, preparation thereof and therapeutic use thereof
06/17/2009EP2069341A1 Pyrrolo[2, 3-b]pyridin-4-yl-benzenesulfonamide compounds as ikk2 inhibitors
06/17/2009EP2069339A2 Substituted piperidinophenyl oxazolidinones
06/17/2009EP2069336A1 Pyridin-4-yl derivatives as immunomodulating agents
06/17/2009EP2069335A1 Pyridin-3-yl derivatives as immunomodulating agents
06/17/2009EP2069334A1 Aspalathin-like dihydrochalcone, extracts from unfermented rooibos and process for preparation
06/17/2009EP2069333A1 Pyrrole derivatives useful for the treatment of cytokine-mediated diseases
06/17/2009EP2069332A2 Azetidine compounds as orexin receptor antagonists
06/17/2009EP2069331A1 1h-indol-6-yl-piperazin-1-yl-methanone-derivatives for use as h3 receptor modulators
06/17/2009EP2069330A1 2 -benzimidazolyl- 6 -morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
06/17/2009EP2069328A2 4-arylalkoxymethyl-4-phenyl piperidines and their use as neurokinin receptor antagonists for the treatment of cns disorders
06/17/2009EP2069327A1 New pyridone derivatives with mch antagonistic activity and medicaments comprising these compounds
06/17/2009EP2069326A2 Bicyclic and tricyclic derivatives as thrombin receptor antagonists
06/17/2009EP2069322A2 Thiophene derivatives as s1p1/edg1 receptor agonists
06/17/2009EP2069321A1 Novel benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof
06/17/2009EP2069320A2 Process for the synthesis of ramelteon and its intermediates
06/17/2009EP2069319A1 Cyclic sulfones useful as mitochondrial sodium-calcium exchangers
06/17/2009EP2069318A1 Phenyl derivatives and their use as immunomodulators
06/17/2009EP2069317A2 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives
06/17/2009EP2069316A1 2,4-diaminoquinazolines for spinal muscular atrophy
06/17/2009EP2069315A2 Quinazolinone and isoquinolinone acetamide derivatives
06/17/2009EP2069314A1 Pyrimidines derivatives and their use as kinase inhibitors
06/17/2009EP2069313A2 Metalloprotease inhibitors
06/17/2009EP2069312A2 Pyridizinone derivatives
06/17/2009EP2069310A2 Sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists
06/17/2009EP2069309A1 Ion channel modulators&uses thereof
06/17/2009EP2069308A2 Azonafide derived tumor and cancer targeting compounds
06/17/2009EP2069305A2 Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
06/17/2009EP2069302A1 Substituted pyridylmethyl bicyclocarboxyamide compounds
06/17/2009EP2069301A1 Process for the preparation of pleuromutilins
06/17/2009EP2069300A2 Multimediator transporter inhibitors for use in treatment of central nervous system disorders
06/17/2009EP2069299A2 Anesthetic compounds
06/17/2009EP2069297A1 2-methylene-(20r,25s)-19,27-dinor-(22e)-vitamin d analogs
06/17/2009EP2069296A2 2-methylene-(20s,25s)-19,27-dinor-(22e)-vitamin d analogs
06/17/2009EP2069295A2 Substituted cyclopentane derivatives as therapeutic agents
06/17/2009EP2069294A1 Soluble epoxide hydrolase inhibitors
06/17/2009EP2069291A1 Hdac inhibitors
06/17/2009EP2069288A1 TARTRATE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS
06/17/2009EP2069285A1 Amorphous form of cinacalcet
06/17/2009EP2069021A2 Methods for treating at least one condition having mt1 receptor, 5ht2b receptor, and l-type calcium channel activity
06/17/2009EP2069020A2 Benzo[d]isoxazole derivatives as c-kit tyrosine kinase inhibitors for the treatment of disorders associated with the over production of histamine
06/17/2009EP2068941A2 Improvement of arginase levels/activity
06/17/2009EP2068938A2 Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors
06/17/2009EP2068934A2 Formulations comprising cyclic compounds
06/17/2009EP2068933A2 Pharmaceutical compositions of clonazepam and methods of use thereof
06/17/2009EP2068931A1 Treatment of fibrosis
06/17/2009EP2068903A2 S-nitrosothiol compounds and related derivatives
06/17/2009EP2068902A2 Tea-derived compostiions and methods of using same for cardiovascular health
06/17/2009EP2068891A2 Composition comprising crustacean gastrolith components, calcium carbonate and its use
06/17/2009EP2068890A2 Use of oritavancin for prevention and treatment of anthrax
06/17/2009EP2068889A1 Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
06/17/2009EP2068887A2 Sp35 antibodies and uses thereof
06/17/2009EP2068886A2 Lipid containing formulations
06/17/2009EP2068885A1 Vitamin d compositions and method of administration to a human being
06/17/2009EP2068884A2 Hydroxycholesterols and its prodrugs for the treatment of insulin resistance and disorders associated therewith
06/17/2009EP2068883A2 Suppression of estrus in mares by a single injection method
06/17/2009EP2068882A2 Method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, a soluble formulation of a pentacyclic or tetracyclic terpenoid and a pharmaceutical composition containing this soluble formulation
06/17/2009EP2068881A2 Method of treating thermoregulatory disfunction with paroxetine
06/17/2009EP2068880A1 Method for treating cancer harboring egfr mutations
06/17/2009EP2068879A2 Pyrroloquinoline quinone drugs and methods of use thereof
06/17/2009EP2068878A2 Rho kinase inhibitors
06/17/2009EP2068877A2 Compounds and methods of modulating angiogenesis
06/17/2009EP2068876A2 Aqueous formulation comprising an antitumor agent
06/17/2009EP2068874A1 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
06/17/2009EP2068873A2 Isoniazid mediated healing of wounds and ulcers
06/17/2009EP2068872A1 Combinations containing a 4-acylaminopyridine derivative
06/17/2009EP2068871A1 Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression
06/17/2009EP2068870A2 Thiophene compounds
06/17/2009EP2068869A2 Novel imidazothiazoles and imidazoxazoles
06/17/2009EP2068868A2 Combination therapy
06/17/2009EP2068867A2 Acylated piperidine derivatives as melanocortin-4 receptor modulators
06/17/2009EP2068866A2 Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists
06/17/2009EP2068865A2 Methods and compositions for therapeutic treatment
06/17/2009EP2068864A2 Therapeutic uses of urolithins
06/17/2009EP2068863A2 Ligustilide derivatives for the treatment of disorders of the central nervous system
06/17/2009EP2068862A2 Substituted oxazole ketone modulators of fatty acid amide hydrolase
06/17/2009EP2068861A2 Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication
06/17/2009EP2068860A2 Treatment of vertigo with acetyl-l-leucine
06/17/2009EP2068859A1 New pharmaceutical compositions comprising a thyroid hormon and their therapeutic use
06/17/2009EP2068858A1 New pharmaceutical compositions comprising diiodothyronine and their therapeutic use
06/17/2009EP2068857A2 Soluble epoxide hydrolase inhibitors
06/17/2009EP2068856A2 Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disorders
1 ... 2692 2693 2694 2695 2696 2697 2698 2699 2700 2701 2702 2703 2704 2705 2706 2707 2708 2709 2710 2711 2712 ... 7860